AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Neonc Technologies Holdings, Inc.
Video analysis: NTHI
All videosNo video analysis for this stock yet. Request one from our team.
News: NTHI
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases.
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase and sale of 3,571,430 shares of the Company's common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase up to 3,571,430 shares of the Company's common stock at a combined purchase price of $4.20 per share (or $4.1999 per pre-funded warrant) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
NeOnc' Phase 2 Data Could Put Cancer on the Ropes
DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI), the Phase 2a question has been answered.
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger
DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.
NeOnc's Clinical Story Is Now the Main Event
DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100's clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer? On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't
DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market. According to the Form 4 transaction information provided by the company's latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and another 3,000 shares on August 17 at an average price of $4.3733.
These Nasdaq Stories Are Heating Up
DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today's catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ: NTHI) has produced the kind of clinical update that can force investors to reconsider an entire biotech story.
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting